|
1
|
Bielack S, Carrle D and Casali PG; ESMO
Guidelines Working Group, : Osteosarcoma: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol.
4 Suppl 20:S137–S139. 2009.
|
|
2
|
Damron TA, Ward WG and Stewart A:
Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National cancer
data base report. Clin Orthop Relat Res. 459:40–47. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tan ML, Choong PF and Dass CR:
Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol
Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bacci G, Briccoli A, Rocca M, Ferrari S,
Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, et
al: Neoadjuvant chemotherapy for osteosarcoma of the extremities
with metastases at presentation: Recent experience at the Rizzoli
Institute in 57 patients treated with cisplatin, doxorubicin, and a
high dose of methotrexate and ifosfamide. Ann Oncol. 14:1126–1134.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rainusso N, Wang LL and Yustein JT: The
adolescent and young adult with cancer: State of the art-bone
tumors. Curr Oncol Rep. 15:296–307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scott KL and Plon SE: CHES1/FOXN3
interacts with Ski-interacting protein and acts as a
transcriptional repressor. Gene. 359:119–126. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun J, Li H, Huo Q, Cui M, Ge C, Zhao F,
Tian H, Chen T, Yao M and Li J: The transcription factor FOXN3
inhibits cell proliferation by downregulating E2F5 expression in
hepatocellular carcinoma cells. Oncotarget. 7:43534–43545.
2016.PubMed/NCBI
|
|
10
|
Balciunaite G, Keller MP, Balciunaite E,
Piali L, Zuklys S, Mathieu YD, Gill J, Boyd R, Sussman DJ and
Holländer GA: Wnt glycoproteins regulate the expression of FoxN1,
the gene defective in nude mice. Nat Immunol. 3:1102–1108. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li C, Lusis AJ, Sparkes R, Tran SM and
Gaynor R: Characterization and chromosomal mapping of the gene
encoding the cellular DNA binding protein HTLF. Genomics.
13:658–664. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang JT, Wang HM, Chang KW, Chen WH, Wen
MC, Hsu YM, Yung BY, Chen IH, Liao CT, Hsieh LL and Cheng AJ:
Identification of differentially expressed genes in oral squamous
cell carcinoma (OSCC): Overexpression of NPM, CDK1 and NDRG1 and
underexpression of CHES1. Int J Cancer. 114:942–949. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Markowski J, Tyszkiewicz T, Jarzab M,
Oczko-Wojciechowska M, Gierek T, Witkowska M, Paluch J, Kowalska M,
Wygoda Z, Lange D and Jarzab B: Metal-proteinase ADAM12, kinesin 14
and checkpoint suppressor 1 as new molecular markers of laryngeal
carcinoma. Eur Arch Otorhinolaryngol. 266:1501–1507. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li S, Mo Z, Yang X, Price SM, Shen MM and
Xiang M: Foxn4 controls the genesis of amacrine and horizontal
cells by retinal progenitors. Neuron. 43:795–807. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katoh M: Identification and
characterization of human FOXN5 and rat Foxn5 genes in silico. Int
J Oncol. 24:1339–1344. 2004.PubMed/NCBI
|
|
16
|
Wang X, He B, Gao Y and Li Y: FOXR2
contributes to cell proliferation and malignancy in human
hepatocellular carcinoma. Tumour Biol. 37:10459–10467. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huot G, Vernier M, Bourdeau V, Doucet L,
Saint-Germain E, Gaumont-Leclerc MF, Moro A and Ferbeyre G:
CHES1/FOXN3 regulates cell proliferation by repressing PIM2 and
protein biosynthesis. Mol Biol Cell. 25:554–565. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gertler AA and Cohen HY: SIRT6, a protein
with many faces. Biogerontology. 14:629–639. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim HS, Xiao C, Wang RH, Lahusen T, Xu X,
Vassilopoulos A, Vazquez-Ortiz G, Jeong WI, Park O, Ki SH, et al:
Hepatic-specific disruption of SIRT6 in mice results in fatty liver
formation due to enhanced glycolysis and triglyceride synthesis.
Cell Metab. 12:224–236. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin H, Hao Y, Zhao Z and Tong Y: Sirtuin 6
contributes to migration and invasion of osteosarcoma cells via the
ERK1/2/MMP9 pathway. FEBS Open Bio. 7:1291–1301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baumhoer D: Pathogenesis and genetics of
osteosarcoma: Current concepts and developments. Der Pathologe.
39:139–145. 2018.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Descamps FJ, Martens E and Opdenakker G:
Analysis of gelatinases in complex biological fluids and tissue
extracts. Lab Invest. 82:1607–1608. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Padala C, Tupurani MA, Puranam K, Gantala
S, Shyamala N, Kondapalli MS, Gundapaneni KK, Mudigonda S, Galimudi
RK, Kupsal K, et al: Synergistic effect of collagenase-1 (MMP1),
stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in
breast cancer. PLoS One. 12:e01844482017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cai X, Zhu H and Li Y: PKCzeta, MMP2 and
MMP9 expression in lung adenocarcinoma and association with a
metastatic phenotype. Mol Med Rep. 16:8301–8306. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jia ZH, Jia Y, Guo FJ, Chen J, Zhang XW
and Cui MH: Phosphorylation of STAT3 at Tyr705 regulates MMP-9
production in epithelial ovarian cancer. PLoS One. 12:e01836222017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bai L, Lin G, Sun L, Liu Y, Huang X, Cao
C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis
and promotes metastasis of non-small cell lung cancer via the
ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schuff M, Rossner A, Wacker SA, Donow C,
Gessert S and Knochel W: FoxN3 is required for craniofacial and eye
development of Xenopus laevis. Dev Dyn. 236:226–239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Samaan G, Yugo D, Rajagopalan S, Wall J,
Donnell R, Goldowitz D, Gopalakrishnan R and Venkatachalam S: Foxn3
is essential for craniofacial development in mice and a putative
candidate involved in human congenital craniofacial defects.
Biochem Biophys Res Commun. 400:60–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nagel S, Meyer C, Kaufmann M, Drexler HG
and MacLeod RA: Deregulated FOX genes in Hodgkin lymphoma. Genes
Chromosomes Cancer. 53:917–933. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cai Y, Mohseny AB, Karperien M, Hogendoorn
PC, Zhou G and Cleton-Jansen AM: Inactive Wnt/beta-catenin pathway
in conventional high-grade osteosarcoma. J Pathol. 220:24–33. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hendrix ND, Wu R, Kuick R, Schwartz DR,
Fearon ER and Cho KR: Fibroblast growth factor 9 has oncogenic
activity and is a downstream target of Wnt signaling in ovarian
endometrioid adenocarcinomas. Cancer Res. 66:1354–1362. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Du Z, Li F, Wang L, Huang H and Xu S:
Regulatory effects of microRNA184 on osteosarcoma via the
Wnt/β-catenin signaling pathway. Mol Med Rep. 18:1917–1924.
2018.PubMed/NCBI
|
|
34
|
Zhao X, Sun S, Xu J, Luo Y, Xin Y and Wang
Y: MicroRNA-152 inhibits cell proliferation of osteosarcoma by
directly targeting Wnt/β-catenin signaling pathway in a
DKK1-dependent manner. Oncol Rep. 40:767–774. 2018.PubMed/NCBI
|
|
35
|
Yu M, Guo D, Cao Z, Xiao L and Wang G:
Inhibitory effect of microRNA-107 on osteosarcoma malignancy
through regulation of Wnt/β-catenin signaling in vitro. Cancer
Invest. 36:175–184. 2018. View Article : Google Scholar : PubMed/NCBI
|
